Aquestive Therapeutics, Inc. (AQST): Depreciation & Amortization
$548.0K
Year ended 2025-12-31
$518.0K
Trailing 12 months to 2026-06-30
-38.8%
3-year compound annual growth
-30.8%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $548.0K | -23.7% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $718.0K | -46.6% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $1.34M | -43.7% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $2.39M | -19.5% | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | $2.96M | -13.9% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $3.44M | +18.5% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $2.90M | -10.2% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $3.24M | n/a | 2020-03-11, From 2018-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $548.0K | -23.7% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.15M | -15.4% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $1.54M | -6.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $1.60M | +14.3% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.28M | +55.0% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $138.0K | -67.2% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $24.0K | -97.1% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $621.0K | +16.3% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $4.32M | +14.2% |
Compare AQST, CPIX, XLO, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗